{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Antibody\u2013drug conjugate", "Antitumor agents", "Nanobody", "SMCC-DM1"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "37129769", "DateCompleted": {"Year": "2024", "Month": "03", "Day": "25"}, "DateRevised": {"Year": "2024", "Month": "04", "Day": "04"}, "Article": {"ArticleDate": [{"Year": "2023", "Month": "05", "Day": "02"}], "Language": ["eng"], "ELocationID": ["10.1007/s11010-023-04741-z"], "Journal": {"ISSN": "1573-4919", "JournalIssue": {"Volume": "479", "Issue": "3", "PubDate": {"Year": "2024", "Month": "Mar"}}, "Title": "Molecular and cellular biochemistry", "ISOAbbreviation": "Mol Cell Biochem"}, "ArticleTitle": "Production and characterization of a camelid single domain anti-CD22 antibody conjugated to DM1.", "Pagination": {"StartPage": "579", "EndPage": "590", "MedlinePgn": "579-590"}, "Abstract": {"AbstractText": ["Antibody drug conjugates (ADCs) with twelve FDA approved drugs, known as a novel category of anti-neoplastic treatment created to merge the monoclonal antibody specificity with cytotoxicity effect of chemotherapy. However, despite many undeniable advantages, ADCs face certain problems, including insufficient internalization after binding, complex structures and large size of full antibodies especially in targeting of solid tumors. Camelid single domain antibody fragments (Nanobody\u00ae) offer solutions to this challenge by providing nanoscale size, high solubility and excellent stability, recombinant expression in bacteria, in vivo enhanced tissue penetration, and conjugation advantages. Here, an anti-human CD22 Nanobody was expressed in E.coli cells and conjugated to Mertansine (DM1) as a cytotoxic payload. The anti-CD22 Nanobody was expressed and purified by Ni-NTA resin. DM1 conjugated anti-CD22 Nanobody was generated by conjugation of SMCC-DM1 to Nanobody lysine groups. The conjugates were characterized using SDS-PAGE and Capillary electrophoresis (CE-SDS), RP-HPLC, and MALDI-TOF mass spectrometry. Additionally, flow cytometry analysis and a competition ELISA were carried out for binding evaluation. Finally, cytotoxicity of conjugates on Raji and Jurkat cell lines was assessed. The drug-to-antibody ratio (DAR) of conjugates was calculated 2.04 using UV spectrometry. SDS-PAGE, CE-SDS, HPLC, and mass spectrometry confirmed conjugation of DM1 to the Nanobody. The obtained results showed the anti-CD22 Nanobody cytotoxicity was enhanced almost 80% by conjugation with DM1. The binding of conjugates was similar to the non-conjugated anti-CD22 Nanobody in flow cytometry experiments. Concludingly, this study successfully suggest that the DM1 conjugated anti-CD22 Nanobody can be used as a novel tumor specific drug delivery system."], "CopyrightInformation": "\u00a9 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature."}, "AuthorList": [{"Identifier": ["0000-0001-7007-2913"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "National Cell Bank of Iran, Pasteur Institute of Iran, Tehran, Iran."}], "LastName": "Ziaei", "ForeName": "Vahab", "Initials": "V"}, {"Identifier": ["0000-0002-6435-9915"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Medicinal Plants and Drugs Research Institute, Shahid Beheshti University, Tehran, Iran."}], "LastName": "Ghassempour", "ForeName": "Alireza", "Initials": "A"}, {"Identifier": ["0000-0002-7693-2926"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran."}], "LastName": "Davami", "ForeName": "Fatemeh", "Initials": "F"}, {"Identifier": ["0000-0002-2503-5336"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran."}], "LastName": "Azarian", "ForeName": "Bahareh", "Initials": "B"}, {"Identifier": ["0000-0002-4839-5123"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Biotechnology Research Center, Venom and Bio Therapeutics Molecules Laboratory, Pasteur Institute of Iran, Tehran, Iran."}], "LastName": "Behdani", "ForeName": "Mahdi", "Initials": "M"}, {"Identifier": ["0000-0003-2439-3155"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Stem Cells and Developmental Biology, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran."}], "LastName": "Dabiri", "ForeName": "Hamed", "Initials": "H"}, {"Identifier": ["0000-0002-3151-152X"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "National Cell Bank of Iran, Pasteur Institute of Iran, Tehran, Iran. habibi_m@pasteur.ac.ir."}], "LastName": "Habibi-Anbouhi", "ForeName": "Mahdi", "Initials": "M"}], "GrantList": [{"GrantID": "BD-9577", "Agency": "Pasteur Institute of Iran, Tehran, Iran", "Country": ""}, {"GrantID": "97012313", "Agency": "Iran National Science Foundation ,Tehran, Iran", "Country": ""}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Netherlands", "MedlineTA": "Mol Cell Biochem", "NlmUniqueID": "0364456", "ISSNLinking": "0300-8177"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Antibodies, Monoclonal"}, {"RegistryNumber": "0", "NameOfSubstance": "Antineoplastic Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "CD22 protein, human"}, {"RegistryNumber": "0", "NameOfSubstance": "Immunoconjugates"}, {"RegistryNumber": "14083FR882", "NameOfSubstance": "Maytansine"}, {"RegistryNumber": "0", "NameOfSubstance": "Sialic Acid Binding Ig-like Lectin 2"}, {"RegistryNumber": "0", "NameOfSubstance": "Single-Domain Antibodies"}], "MeshHeadingList": [{"QualifierName": ["pharmacology"], "DescriptorName": "Antibodies, Monoclonal"}, {"QualifierName": ["immunology"], "DescriptorName": "Antineoplastic Agents"}, {"QualifierName": [], "DescriptorName": "Cell Line, Tumor"}, {"QualifierName": ["chemistry", "therapeutic use"], "DescriptorName": "Immunoconjugates"}, {"QualifierName": ["chemistry"], "DescriptorName": "Maytansine"}, {"QualifierName": ["drug therapy"], "DescriptorName": "Neoplasms"}, {"QualifierName": ["immunology"], "DescriptorName": "Sialic Acid Binding Ig-like Lectin 2"}, {"QualifierName": [], "DescriptorName": "Single-Domain Antibodies"}, {"QualifierName": ["immunology"], "DescriptorName": "Camelidae"}]}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Chen L, Wang L, Shion H et al (2016) In-depth structural characterization of Kadcyla\u00ae(ado-trastuzumab emtansine) and its biosimilar candidate. InMAbs 8:1210\u20131223. https://doi.org/10.1080/19420862.2016.1204502", "ArticleIdList": ["10.1080/19420862.2016.1204502"]}, {"Citation": "Esnault C, Schrama D, Houben R et al (2022) Antibody-drug conjugates as an emerging therapy in oncodermatology. Cancers (Basel) 14:778. https://doi.org/10.3390/cancers14030778", "ArticleIdList": ["10.3390/cancers14030778", "35159045"]}, {"Citation": "Coleman N, Yap TA, Heymach JV, Meric-Bernstam F, Le X (2023) Antibody-drug conjugates in lung cancer: dawn of a new era? npj Precision Oncol 7(1):5. https://doi.org/10.1038/s41698-022-00338-9", "ArticleIdList": ["10.1038/s41698-022-00338-9"]}, {"Citation": "Leung D, Wurst JM, Liu T et al (2020) Antibody conjugates-recent advances and future innovations. Antibodies (Basal) 9:2. https://doi.org/10.3390/antib9010002", "ArticleIdList": ["10.3390/antib9010002"]}, {"Citation": "Chan SK, Choong YS et al (2018) Chemoenzymatic bioconjugation of antibodies: linking proteins for biomedical applications. Enzymes Food Technol. https://doi.org/10.1007/978-981-13-1933-4_18", "ArticleIdList": ["10.1007/978-981-13-1933-4_18"]}, {"Citation": "Benjamin SR, Jackson CP, Fang S et al (2019) Thiolation of Q295: site-specific conjugation of hydrophobic payloads without the need for genetic engineering. Mol Pharmaceutics 16:2795\u20132807. https://doi.org/10.1021/acs.molpharmaceut.9b00323", "ArticleIdList": ["10.1021/acs.molpharmaceut.9b00323"]}, {"Citation": "Merkul E, Sijbrandi NJ, Muns JA et al (2019) First platinum (II)-based metal-organic linker technology (Lx\u00ae) for a plug-and-play development of antibody-drug conjugates (ADCs). Expert Opin Drug Deliv 16:783\u2013793. https://doi.org/10.1080/17425247.2019.1645118", "ArticleIdList": ["10.1080/17425247.2019.1645118", "31327255"]}, {"Citation": "Fernandes CF, Pereira SS, Luiz MB et al (2021) Engineering of single-domain antibodies for next-generation snakebite antivenoms. Int J Biol Macromol 185:240\u2013250. https://doi.org/10.1016/j.ijbiomac.2021.06.043", "ArticleIdList": ["10.1016/j.ijbiomac.2021.06.043", "34118288"]}, {"Citation": "Arezumand R, Alibakhshi A et al (2017) Nanobodies as novel agents for targeting angiogenesis in solid cancers. Front Immunol 8:1746", "ArticleIdList": ["10.3389/fimmu.2017.01746", "29276515", "5727022"]}, {"Citation": "Bathula NV, Bommadevara H et al (2021) Nanobodies: the future of antibody-based immune therapeutics. Cancer Biother Radiopharm 36:109\u2013122. https://doi.org/10.1089/cbr.2020.3941", "ArticleIdList": ["10.1089/cbr.2020.3941", "32936001"]}, {"Citation": "Muyldermans S (2021) Applications of nanobodies. Annu Rev Anim Biosci 9:401\u2013421. https://doi.org/10.1146/annurev-animal-021419-083831", "ArticleIdList": ["10.1146/annurev-animal-021419-083831", "33233943"]}, {"Citation": "Liu M, Li L, Jin D et al (2021) Nanobody\u2014A versatile tool for cancer diagnosis and therapeutics. Wiley Interdiscip Rev: Nanomed Nanobiotechnol 13:e1697", "ArticleIdList": ["33470555"]}, {"Citation": "Fang T, Duarte JN, Ling J et al (2016) Structurally defined \u03b1MHC-II nanobody\u2013drug conjugates: a therapeutic and imaging system for B-cell lymphoma. Angew Chem Int Ed 55:2416\u20132420. https://doi.org/10.1002/anie.201509432", "ArticleIdList": ["10.1002/anie.201509432"]}, {"Citation": "Jov\u010devska I et al (2020) a The therapeutic potential of nanobodies. BioDrugs Clin Immunotherap Biopharm Gene Therapy 34:11\u201326. https://doi.org/10.1007/s40259-019-00392-z", "ArticleIdList": ["10.1007/s40259-019-00392-z"]}, {"Citation": "Axup JY, Bajjuri KM, Ritland M et al (2012) Synthesis of site-specific antibody-drug conjugates using unnatural amino acids. Proc Natl Acad Sci 109:16101\u201316106. https://doi.org/10.1073/pnas.1211023109", "ArticleIdList": ["10.1073/pnas.1211023109", "22988081", "3479532"]}, {"Citation": "Stokke JL, Bhojwani D (2021) Antibody\u2013drug conjugates for the treatment of acute pediatric leukemia. J Clin Med 10(16):3556. https://doi.org/10.3390/jcm10163556", "ArticleIdList": ["10.3390/jcm10163556", "34441852", "8396964"]}, {"Citation": "Yaghoubi S, Karimi MH, Lotfinia M, Gharibi T, Mahi-Birjand M, Kavi E, Abdollahpour-Alitappeh M (2020) Potential drugs used in the antibody\u2013drug conjugate (ADC) architecture for cancer therapy. J Cell Physiol 235(1):31\u201364. https://doi.org/10.1002/jcp.28967", "ArticleIdList": ["10.1002/jcp.28967", "31215038"]}, {"Citation": "Faraji F, Tajik N, Behdani M et al (2018) Development and characterization of a camelid single-domain antibody directed to human CD22 biomarker. Biotechnol Appl Biochem 65:718\u2013725. https://doi.org/10.1002/bab.1654", "ArticleIdList": ["10.1002/bab.1654", "29543347"]}, {"Citation": "Abedi M, Cohan RA, Mahboudi F et al (2019) MALDI-MS: a rapid and reliable method for drug-to-antibody ratio determination of antibody-drug conjugates. Iran Biomed J 23:395. https://doi.org/10.29252/ibj.23.6.395", "ArticleIdList": ["10.29252/ibj.23.6.395", "31104399", "6800535"]}, {"Citation": "Felten C, Solano OS (2010) Capillary electrophoresis in quality control: PART I: application for therapeutic proteins. Beckman Coulter pp 1\u20138"}, {"Citation": "Faraji F, Habibi-Anbouhi M, Behdani M et al (2020) Functional study of a camelid single domain anti-CD22 antibody. Int J Pept Res Ther 26:633\u2013639. https://doi.org/10.1007/s10989-019-09870-y", "ArticleIdList": ["10.1007/s10989-019-09870-y"]}, {"Citation": "Panikar SS, Banu N, Haramati J et al (2021) Nanobodies as efficient drug-carriers: progress and trends in chemotherapy. J Controlled Relaese 334:389\u2013412. https://doi.org/10.1016/j.jconrel.2021.05.004", "ArticleIdList": ["10.1016/j.jconrel.2021.05.004"]}, {"Citation": "Bartlett NL, Sharman JP, Oki Y et al (2013) A phase 2 study of brentuximab vedotin in patients with relapsed or refractory CD30-positive non-Hodgkin lymphomas: interim results in patients with DLBCL and other B-cell lymphomas. Blood 122:848. https://doi.org/10.1182/blood.V122.21.848.848", "ArticleIdList": ["10.1182/blood.V122.21.848.848"]}, {"Citation": "Staudacher AH, Brown MP (2017) Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required? Br J Cancer 117:1736\u20131742. https://doi.org/10.1038/bjc.2017.367", "ArticleIdList": ["10.1038/bjc.2017.367", "29065110", "5729478"]}, {"Citation": "Polson AG, Calemine-Fenaux J et al (2009) Antibody-drug conjugates for the treatment of non\u2013hodgkin\u2019s lymphoma: target and linker-drug selection. Can Res 69:2358\u20132364. https://doi.org/10.1158/0008-5472.CAN-08-2250", "ArticleIdList": ["10.1158/0008-5472.CAN-08-2250"]}, {"Citation": "Davis TK, Jennings ME (2022) Site-specific conjugation quantitation of a cysteine-conjugated antibody-drug conjugate using stable isotope labeling peptide mapping LC\u2013MS/MS analysis. Anal Chem 94:2772\u20132778. https://doi.org/10.1021/acs.analchem.1c04025", "ArticleIdList": ["10.1021/acs.analchem.1c04025", "35100801"]}, {"Citation": "Chen Y (2013) Drug-to-antibody ratio (DAR) by UV/Vis spectroscopy, in antibody-drug conjugates. In Antibody-Drug Conjugates 1045:267\u2013273. https://doi.org/10.1007/978-1-62703-541-5_16", "ArticleIdList": ["10.1007/978-1-62703-541-5_16"]}, {"Citation": "Kim MT, Chen Y, Marhoul J et al (2014) Statistical modeling of the drug load distribution on trastuzumab emtansine (Kadcyla), a lysine-linked antibody drug conjugate. Bioconjug Chem 25:1223\u20131232. https://doi.org/10.1021/bc5000109", "ArticleIdList": ["10.1021/bc5000109", "24873191"]}, {"Citation": "Debie P, Van Quathem J, Hansen I et al (2017) Effect of dye and conjugation chemistry on the biodistribution profile of near-infrared-labeled nanobodies as tracers for image guided surgery. Mol Pharm 14:1145\u20131153. https://doi.org/10.1021/acs.molpharmaceut.6b01053", "ArticleIdList": ["10.1021/acs.molpharmaceut.6b01053", "28245129"]}, {"Citation": "Beck A, Terral G, Debaene F et al (2016) Cutting-edge mass spectrometry methods for the multi-level structural characterization of antibody-drug conjugates. Expert Rev Proteomics 13:157\u2013183. https://doi.org/10.1586/14789450.2016.1132167", "ArticleIdList": ["10.1586/14789450.2016.1132167", "26653789"]}, {"Citation": "Aguilar MI, Hearn MT (1996) High-resolution reversed-phase high-performance liquid chromatography of peptides and proteins. In Methods Enzymol 270:3\u201326. https://doi.org/10.1016/S0076-6879(96)70003-4", "ArticleIdList": ["10.1016/S0076-6879(96)70003-4"]}, {"Citation": "Peciak K, Laurine E, Tommasi R, Choi J-W, Brocchini SJCs (2019) Site-selective protein conjugation at histidine. Chem Sci 10:427\u2013439. https://doi.org/10.1039/C8SC03355B", "ArticleIdList": ["10.1039/C8SC03355B", "30809337"]}, {"Citation": "Gong L, Ding H, Long NE et al (2018) A 3E8. scFv. Cys-IR800 conjugate targeting TAG-72 in an orthotopic colorectal cancer model. Mol Imag Biol 20:47\u201354. https://doi.org/10.1007/s11307-017-1096-4", "ArticleIdList": ["10.1007/s11307-017-1096-4"]}, {"Citation": "Hentrich C, Kellmann SJ, Putyrski M et al (2021) Periplasmic expression of SpyTagged antibody fragments enables rapid modular antibody assembly. Cell Chem Biol 28:813-824.e6. https://doi.org/10.1016/j.chembiol.2021.01.011", "ArticleIdList": ["10.1016/j.chembiol.2021.01.011", "33529581"]}, {"Citation": "Wiggins B, Liu-Shin L, Yamaguchi H et al (2015) Characterization of cysteine-linked conjugation profiles of immunoglobulin G1 and immunoglobulin G2 antibody\u2013drug conjugates. J Pharm Sci 104:1362\u20131372. https://doi.org/10.1002/jps.24338", "ArticleIdList": ["10.1002/jps.24338", "25631158"]}, {"Citation": "Liu J, Zhao H, Volk KJ et al (1996) Analysis of monoclonal antibody and immunoconjugate digests by capillary electrophoresis and capillary liquid chromatography. J Chromatogr A. https://doi.org/10.1016/0021-9673", "ArticleIdList": ["10.1016/0021-9673", "8962506"]}, {"Citation": "Marder P, Apelgren LD, Bumol TF et al (1987) Comparative analysis of monoclonal antibody-drug conjugate binding by flow cytometry. J Immunol Methods 96:165\u2013170. https://doi.org/10.1016/0022-1759(87)90310-3", "ArticleIdList": ["10.1016/0022-1759(87)90310-3", "3492560"]}, {"Citation": "Asano S, Patterson JT, Gaj T (2014) Site-selective labeling of a lysine residue in human serum albumin. Angew Chem Int Ed 53:11783\u201311786. https://doi.org/10.1002/anie.201405924", "ArticleIdList": ["10.1002/anie.201405924"]}, {"Citation": "Choi J, Vaidyanathan G, Koumarianou E et al (2018) Astatine-211 labeled anti-HER2 5F7 single domain antibody fragment conjugates: radiolabeling and preliminary evaluation. Nucl Med Biol 56:10\u201320. https://doi.org/10.1016/j.nucmedbio.2017.09.003", "ArticleIdList": ["10.1016/j.nucmedbio.2017.09.003", "29031230"]}, {"Citation": "Martineau P (2010) Affinity measurements by competition ELISA. Antibody Eng. https://doi.org/10.1007/978-3-642-01144-3_41", "ArticleIdList": ["10.1007/978-3-642-01144-3_41"]}, {"Citation": "Jin BK, Odongo S, Radwanska M, Magez S (2023) Nanobodies: a review of generation, diagnostics and therapeutics. Int J Mol Sci 24(6):5994. https://doi.org/10.3390/ijms24065994", "ArticleIdList": ["10.3390/ijms24065994", "36983063", "10057852"]}, {"Citation": "Gandullo-S\u00e1nchez L, Pandiella A (2023) An anti-EGFR antibody-drug conjugate overcomes resistance to HER2-targeted drugs. Cancer Lett 554:216024. https://doi.org/10.1016/j.canlet.2022.216024", "ArticleIdList": ["10.1016/j.canlet.2022.216024", "36455759"]}, {"Citation": "Sadeghi S, Olevsky O, Hurvitz SA (2014) Profiling and targeting HER2-positive breast cancer using trastuzumab emtansine. Pharmacogenomics Personalized Med. https://doi.org/10.2147/PGPM.S47524", "ArticleIdList": ["10.2147/PGPM.S47524"]}], "ReferenceList": []}], "History": [{"Year": "2023", "Month": "3", "Day": "1"}, {"Year": "2023", "Month": "4", "Day": "11"}, {"Year": "2024", "Month": "3", "Day": "25", "Hour": "6", "Minute": "42"}, {"Year": "2023", "Month": "5", "Day": "2", "Hour": "12", "Minute": "43"}, {"Year": "2023", "Month": "5", "Day": "2", "Hour": "11", "Minute": "10"}], "PublicationStatus": "ppublish", "ArticleIdList": ["37129769", "10.1007/s11010-023-04741-z", "10.1007/s11010-023-04741-z"]}}], "PubmedBookArticle": []}